TOKYO–(BUSINESS WIRE)–Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereinafter “SEEDSUPPLY”) hereby announce the start of joint research.
SEED SUPPLY (https://www.seedsupply.co.jp/) offers an agile drug discovery process for small molecules that uses binder selection technology as a proprietary method of compound screening. This technology can perform compound screening of any protein or RNA, thereby providing drug discovery seeds for various drug discovery targets, including those for which measuring biochemical activity is difficult. Additionally, a database of binding compounds built for specific drug discovery target classes will be used for target selection, thereby improving the efficiency and success rate of drug discovery processes. Furthermore, the database has the potential for wider application.
Elix (https://www.elix-inc.com/) is an AI-based drug discovery company with a mission to “Rethink Drug Discovery”. To reduce costs and time while increasing the success rate of the drug discovery pipeline, Elix is focusing on the use of machine learning in projects for pharmaceutical companies, universities and research institutes. Elix has developed and launched “Elix Discovery™”, the all-in-one platform for AI drug discovery, providing everything from models for property prediction and molecular design, to consulting and support for implemented in a single package (https://www.elix-inc.com/news/newsrelease/1620/). In addition to currently providing drug discovery support, Elix is also considering future drug discovery internally.
In this joint research project, SEEDSUPPLY will use Elix’s proprietary artificial intelligence technology with the aim of dramatically increasing the efficiency of breeding processes. Elix will integrate SEEDSUPPLY’s wealth of data, particularly its data on key drug discovery targets such as membrane proteins, into the AI training pipeline, advancing the technology to silicone techniques to screen for compounds with superior properties.
Elix and SEEDSUPPLY aim to use their respective strengths to reduce the cost and time of small molecule drug discovery and target targets that have proven difficult for conventional drug discovery approaches.
Comments from Elix CEO Shinya Yuki
By combining data acquired through SEEDSUPPLY’s proprietary technology and our proprietary AI models, we hope to find even more unique technological developments. We believe this technology will provide great opportunities for screening very difficult targets at low cost in short timeframes, and in efficiently searching for expansive chemical spaces.
Comments from SEEDSUPPLY CEO Naoki Tarui
Our company’s binder compound database is of the highest quality, as all of its content has been measured using the same method. By combining it with Elix’s superior AI technology, we hope to create new developments in AI drug discovery technology.